Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study

Primary cutaneous T-cell lymphomas (CTCLs), a heteroge-neous group of extranodal non-Hodgkin lymphomas involving the skin

[1]  M. Suarez‐Almazor,et al.  Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation , 2021, Journal for ImmunoTherapy of Cancer.

[2]  T. Ishikawa,et al.  Haploidentical Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide for Sézary Syndrome , 2020, Case Reports in Oncology.

[3]  L. Wilson,et al.  Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas , 2020, Leukemia & lymphoma.

[4]  L. French,et al.  Long–Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T–Cell Lymphoma; Results From a Single Institution Analysis , 2020, Frontiers in Medicine.

[5]  R. Varadhan,et al.  Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: a Retrospective Cohort Study. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  P. Sharma,et al.  Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors , 2020, Cancer.

[7]  S. Montoto,et al.  Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Miyamoto,et al.  Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome , 2020, Hematological oncology.

[9]  A. Kallies,et al.  Precursor exhausted T cells: key to successful immunotherapy? , 2019, Nature Reviews Immunology.

[10]  R. Tao,et al.  Haploidentical hematopoietic cell transplantation for mycosis fungoides/Sezary syndrome , 2019, Leukemia & lymphoma.

[11]  H. Tun,et al.  Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T-cell lymphoma: results of a systematic review/meta-analysis. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  T. Tejasvi,et al.  Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management , 2019, American journal of hematology.

[13]  N. Kröger,et al.  Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Richard J. Jones,et al.  Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. , 2018, Blood advances.

[15]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[16]  N. Ifrah,et al.  [Cutaneous and systemic T-cell lymphoma treated with haploidentical bone marrow transplantation]. , 2018, Annales de dermatologie et de venereologie.

[17]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[18]  R. Houot,et al.  Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.

[19]  Sonali M. Smith,et al.  Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Oki,et al.  Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Duvic,et al.  Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. , 2015, Clinical lymphoma, myeloma & leukemia.

[22]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[23]  Alan M. Miller,et al.  ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME , 2014, Bone Marrow Transplantation.

[24]  M. Horowitz,et al.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.

[25]  Richard J. Jones,et al.  Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  S. Forman,et al.  Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas , 2011, Bone Marrow Transplantation.

[27]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[28]  R. Hoppe,et al.  A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  N. Schmitz,et al.  Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma , 2008, Bone Marrow Transplantation.

[31]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.